Precision Personalized Therapy
薬効バイオマーカー

BTK Target Occupancy and BTK mutation Assays for Leukemia and Non-Hodgkin Lymphoma Patients
GLP及びnon-GLPサービス

Select the right BTK inhibitors and right dose regimen/frequency to treat CLL/non-Hodgkin

Select the right BTK inhibitors and right dose regimen/frequency to treat CLL/non-Hodgkin

Safety_1
  • Establish icon

    Identify a patient’s unique BTK mutation status See Data

    Identify a patient’s unique BTK mutation status See Data

  • Determine icon

    On-target engagement with the right drug to determine the %BTK occupancy of a drug and its active metabolites in blood cells See Data

    On-target engagement with the right drug to determine the %BTK occupancy of a drug and its active metabolites in blood cells See Data

  • Monitor icon

    Select treatment by determining appropriate dosing level & frequency to achieve a clinical response See Data

    Select treatment by determining appropriate dosing level & frequency to achieve a clinical response See Data

  • Dosing icon

    Monitor drug off-target effects to define dosing regimens & reduce safety risks See Data

    Monitor drug off-target effects to define dosing regimens & reduce safety risks See Data

Improve and balance clinical response and drug safety for leukemia and non-Hodgkin’s lymphoma patients

Improve and balance clinical response and drug safety for leukemia and non-Hodgkin’s lymphoma patients

Nextcea uses advanced LC-MS/MS platforms to identify and quantitate patients’ BTK mutation status, BTK inhibitor %occupancy and off-target effects.

Nextcea uses advanced LC-MS/MS platforms to identify and quantitate patients’ BTK mutation status, BTK inhibitor %occupancy and off-target effects.

Our clinical blood assays allow physicians and pharmaceutical sponsors to:

Our clinical blood assays allow physicians and pharmaceutical sponsors to:

  • Select the “right” treatment for cancer patients based on their BTK mutation status (covalent vs. non-covalent drugs or combination of both).

    Select the “right” treatment for cancer patients based on their BTK mutation status (covalent vs. non-covalent drugs or combination of both).

  • Evaluate dosing requirements for patients based the %occupancy of BTK inhibitors and active metabolites

    Evaluate dosing requirements for patients based the %occupancy of BTK inhibitors and active metabolites

  • Reduce safety risks associated with the off-target effects of BTK inhibitors (ex. bleeding associated with ibrutinib).

    Reduce safety risks associated with the off-target effects of BTK inhibitors (ex. bleeding associated with ibrutinib).

Advanced UPLC-MS/MS Services

Advanced UPLC-MS/MS Services

  • Identify and profile the percentage of functional BTK C481 mutations in patients over time

    Identify and profile the percentage of functional BTK C481 mutations in patients over time

  • Absolutely quantitate the target %occupancy of BTK inhibitors (ex. ibrutinib, acalabrutinib, zanubrutinib) in patients’ white blood cells.

    Absolutely quantitate the target %occupancy of BTK inhibitors (ex. ibrutinib, acalabrutinib, zanubrutinib) in patients’ white blood cells.

  • Correlate the %occupancy associated with clinical response (ex. the change in white blood cell count) in individual patients

    Correlate the %occupancy associated with clinical response (ex. the change in white blood cell count) in individual patients